Efficacy and safety of immunosuppressants and immunomodulators in juvenile myasthenia gravis: a systematic review and meta-analysis - PubMed
6 hours ago
- #meta-analysis
- #immunosuppressants
- #juvenile myasthenia gravis
- The meta-analysis explores the efficacy and safety of immunosuppressants and immunomodulators in treating juvenile myasthenia gravis (JMG).
- A systematic search was conducted from 2000 to 2025, including 3029 articles, with 9 cohort and case-control studies, 11 case series, 3 single-arm studies, and 1 randomized controlled trial.
- Tacrolimus showed significant reduction in QMG and MG-ADL scores, with a response rate of 0.862 (95% CI: 0.716-0.967) and allowed for steroid dosage reduction.
- Monoclonal antibodies had a high response rate of 0.993 (95% CI: 0.935-1.000) in 6 studies involving 67 patients.
- Glucocorticoid monotherapy was more effective for isolated ocular myasthenia gravis (OMG) than for patients with both OMG and generalized myasthenia gravis (GMG).
- IVIG therapy showed a response rate ranging from 47.06% to 94.3% in 4 studies.
- Most included studies were single-center retrospective observational studies, highlighting the need for future prospective multicenter studies.